Cortexyme (CRTX) Competitors $1.40 +0.02 (+1.45%) As of 03/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, IKT, IPHA, MOLN, CCCC, CGEN, ALEC, and LXEOShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Inhibikase Therapeutics (IKT), Innate Pharma (IPHA), Molecular Partners (MOLN), C4 Therapeutics (CCCC), Compugen (CGEN), Alector (ALEC), and Lexeo Therapeutics (LXEO). Cortexyme vs. Omnicell HealthStream Veradigm Inhibikase Therapeutics Innate Pharma Molecular Partners C4 Therapeutics Compugen Alector Lexeo Therapeutics Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Do insiders and institutionals have more ownership in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.6% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer CRTX or OMCL? Omnicell received 347 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.80% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformCortexymeOutperform Votes15464.44% Underperform Votes8535.56% OmnicellOutperform Votes50166.80% Underperform Votes24933.20% Do analysts rate CRTX or OMCL? Omnicell has a consensus price target of $51.00, indicating a potential upside of 47.95%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, CRTX or OMCL? Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Which has stronger valuation and earnings, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.47Omnicell$1.11B1.45$12.53M$0.27127.67 Is CRTX or OMCL more profitable? Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 1.13%3.82%2.07% Does the media favor CRTX or OMCL? In the previous week, Omnicell had 9 more articles in the media than Cortexyme. MarketBeat recorded 9 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 0.80 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Omnicell Positive SummaryOmnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks. Remove Ads Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.21M$3.03B$5.68B$8.31BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.4729.9524.5519.25Price / SalesN/A447.85395.7294.09Price / CashN/A168.6838.1634.64Price / Book0.354.227.064.46Net Income-$89.94M-$71.72M$3.19B$247.07M7 Day Performance1.45%-2.22%1.49%3.05%1 Month PerformanceN/A-9.53%5.87%-2.85%1 Year Performance16.67%-22.57%14.94%4.63% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.40+1.4%N/A+15.0%$42.21MN/A-0.4755OMCLOmnicell2.472 of 5 stars$35.14+3.5%$51.00+45.1%+25.8%$1.64B$1.11B130.153,650Analyst DowngradeHSTMHealthStream4.0574 of 5 stars$32.03+1.5%$32.00-0.1%+21.2%$974.80M$291.65M49.281,140Positive NewsMDRXVeradigm2.9235 of 5 stars$4.25-5.6%$14.00+229.4%-46.5%$457.47M$1.53B0.008,000Analyst ForecastGap DownIKTInhibikase Therapeutics0.9528 of 5 stars$2.37flat$6.50+174.3%+6.3%$164.39M$260,000.00-0.896IPHAInnate Pharma2.3095 of 5 stars$1.94-5.1%$11.50+494.3%-18.4%$162.21M$24.85M0.00220Upcoming EarningsNews CoverageMOLNMolecular Partners1.5542 of 5 stars$3.97+0.9%$12.00+202.6%-2.5%$160.09M$4.97M-1.84180CCCCC4 Therapeutics1.7476 of 5 stars$2.22+4.7%$12.50+463.1%-73.0%$157.60M$35.58M-1.31150CGENCompugen2.146 of 5 stars$1.62+3.2%$4.00+146.9%-38.6%$144.56M$27.86M81.0070Positive NewsALECAlector3.4439 of 5 stars$1.37+1.5%$3.50+155.5%-77.1%$135.75M$100.56M-0.81270LXEOLexeo Therapeutics2.3777 of 5 stars$4.09+50.9%$23.60+477.0%-71.8%$135.24M$650,000.00-1.2958Earnings ReportAnalyst ForecastNews CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Inhibikase Therapeutics Alternatives Innate Pharma Alternatives Molecular Partners Alternatives C4 Therapeutics Alternatives Compugen Alternatives Alector Alternatives Lexeo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRTX Stock Free CRTX Stock Alerts